Difference between revisions of "PET Amyloid Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
(27 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
:Co-chairs: Satoshi Minoshima, MD, PhD; Anne M. Smith, PhD; Dawn C. Matthews, MS, MBA
 
:Co-chairs: Satoshi Minoshima, MD, PhD; Anne M. Smith, PhD; Dawn C. Matthews, MS, MBA
  
:Secretary: Julie Lisiecki
+
:RSNA Staff Support: Julie Lisiecki
 
* [http://tinyurl.com/QIBA-PET-Amyloid-Roster Roster]
 
* [http://tinyurl.com/QIBA-PET-Amyloid-Roster Roster]
  
Line 20: Line 20:
 
==PET Amyloid Meetings/Call Summaries==
 
==PET Amyloid Meetings/Call Summaries==
  
*[[Media:04_13_2018_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL-dcm-esp.pdf|April 13, 2018]]
+
*[[Media:2020_08-14_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL-AMS.pdf|August 14, 2020]]
*[[Media:03_09_2018_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL.pdf|March 9, 2018]]
+
*[[Media:2020_06-12_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|June 12, 2020]]
*[[Media:02_09_2018_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL-dcm.pdf|February 9, 2018]]
+
*[[Media:2020_05-08_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|May 8, 2020]]
 +
*[[Media:2020_03-13_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL-AMS-2.pdf|March 13, 2020]]
 +
*[[Media:2020_02-14_QIBA_Amyloid_Biomarker_Ctte_Call_Summary_FINAL.pdf|February 14, 2020]]
  
 
'''''[[PET Amyloid BC Call Summaries Archive]]'''''
 
'''''[[PET Amyloid BC Call Summaries Archive]]'''''
Line 55: Line 57:
 
==Presentations and Reports==
 
==Presentations and Reports==
  
 +
*[[Media:08Jun2018_BCMeeting_Amyloid_updated.pdf | 06 08 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
 
*[[Media:11May2018_BCMeeting_Amyloid_updated.pdf | 05 11 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
 
*[[Media:11May2018_BCMeeting_Amyloid_updated.pdf | 05 11 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
 
*[[Media:13April2018_BCMeeting_Amyloid.pdf | 04 13 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
 
*[[Media:13April2018_BCMeeting_Amyloid.pdf | 04 13 2018 QIBA PET Amyloid Biomarker Committee Presentation Slides - presented by Ms. Matthews]]
Line 75: Line 78:
  
 
*[[Media:02 13 2015 QIBA PET Amyloid Biomarker Committee Presentation Notes.pdf|02 13 2015 QIBA PET Amyloid Biomarker Committee Presentation Notes - presented by Dr. Perlman]]
 
*[[Media:02 13 2015 QIBA PET Amyloid Biomarker Committee Presentation Notes.pdf|02 13 2015 QIBA PET Amyloid Biomarker Committee Presentation Notes - presented by Dr. Perlman]]
 +
 +
==QIBA Funded Projects==
 +
 +
====Round 4====
 +
*[[Media:Amyloid Profile Continued Support with Brain Phantom Development.pdf | Project (X) Amyloid Profile Continued Support with Brain Phantom Development (University of Iowa)]]
 +
 +
====Round 5====
 +
*[[Media:Analyses to Support Amyloid Imaging Profile Development.pdf | Project (A) Analyses to Support Amyloid Imaging Profile Development (ADM Diagnostics, LLC)]]
 +
 +
*[[Media:Amyloid Brain PET Test-Retest Meta-analysis.pdf | Project (E) Amyloid Brain PET Test-Retest Meta-analysis (Johns Hopkins University)]]
 +
 +
*[[Media:A PET-Metabolic Tumor Volume-DRO.pdf | Project (I) A PET-Metabolic Tumor Volume-Digital Reference Object (PET-MTV-DRO) (University of Washington)]]
 +
 +
*[[Media:A Procedure to Facilitate Greater Standardization of PET Spatial Resolution.pdf | Project (J) A Procedure to Facilitate Greater Standardization of PET Spatial Resolution (Johns Hopkins University)]]

Revision as of 19:21, 25 August 2020

Co-chairs: Satoshi Minoshima, MD, PhD; Anne M. Smith, PhD; Dawn C. Matthews, MS, MBA
RSNA Staff Support: Julie Lisiecki


Project Snapshot

There is a draft Profile, and current outline of the Claim is:

  • SUVr will be the measurand
  • The claim will have two components
1) Cross-sectional: single subject scan
2) Longitudinal: following subject over time

Due to the complexity of having multiple PET Amyloid tracers, a subgroup, the Test-retest Group, has been formed including academics and industry representatives from all of the major PET Amyloid tracer vendors. This group will evaluate the published data on amyloid imaging precision, to determine what level of precision can be claimed in the Profile. The committee’s goal is to have a final draft Profile by December, 2015.

Collaborations: RSNA QIBA is now an affiliate of GAAIN (Global Alzheimer’s Association International Network)

PET Amyloid Meetings/Call Summaries

PET Amyloid BC Call Summaries Archive

PET Amyloid Profile Development

Profile Supporting Material

Working Documents

Presentations and Reports

QIBA Funded Projects

Round 4

Round 5